Replimune Group (NASDAQ:REPL) Stock Rating Lowered by Zacks Investment Research

Replimune Group (NASDAQ:REPL) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday, Zacks.com reports.

According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company’s product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. “

Several other equities analysts also recently commented on REPL. HC Wainwright reaffirmed a “buy” rating and issued a $26.00 target price on shares of Replimune Group in a research report on Monday, September 30th. Chardan Capital reiterated a “buy” rating and issued a $28.00 target price on shares of Replimune Group in a research note on Thursday, October 24th. ValuEngine upgraded shares of Replimune Group from a “sell” rating to a “hold” rating in a research note on Monday, November 4th. Finally, Roth Capital upped their target price on shares of Replimune Group from $20.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, November 11th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Replimune Group presently has a consensus rating of “Buy” and an average price target of $25.17.

Shares of REPL stock traded down $1.44 during mid-day trading on Friday, reaching $12.20. The stock had a trading volume of 819,800 shares, compared to its average volume of 194,376. The firm’s 50 day simple moving average is $14.49 and its 200 day simple moving average is $13.44. The firm has a market cap of $436.60 million, a PE ratio of -9.17 and a beta of 3.30. The company has a quick ratio of 9.79, a current ratio of 9.85 and a debt-to-equity ratio of 0.16. Replimune Group has a one year low of $8.88 and a one year high of $18.25.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Monday, November 11th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Sell-side analysts forecast that Replimune Group will post -1.4 earnings per share for the current fiscal year.

In related news, CEO Robert Coffin sold 48,500 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $16.92, for a total transaction of $820,620.00. Also, COO Colin Love sold 11,250 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $17.05, for a total transaction of $191,812.50. In the last quarter, insiders sold 200,000 shares of company stock worth $3,395,500. Insiders own 63.18% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Morgan Stanley lifted its position in Replimune Group by 793.0% during the second quarter. Morgan Stanley now owns 20,709 shares of the company’s stock valued at $304,000 after purchasing an additional 18,390 shares during the period. Wells Fargo & Company MN lifted its position in Replimune Group by 211.3% during the second quarter. Wells Fargo & Company MN now owns 23,090 shares of the company’s stock valued at $338,000 after purchasing an additional 15,672 shares during the period. Northern Trust Corp lifted its position in Replimune Group by 1.2% during the second quarter. Northern Trust Corp now owns 123,931 shares of the company’s stock valued at $1,817,000 after purchasing an additional 1,437 shares during the period. Citadel Advisors LLC lifted its position in Replimune Group by 5.7% during the second quarter. Citadel Advisors LLC now owns 186,281 shares of the company’s stock valued at $2,731,000 after purchasing an additional 10,009 shares during the period. Finally, Vanguard Group Inc. lifted its position in Replimune Group by 7.3% during the second quarter. Vanguard Group Inc. now owns 536,564 shares of the company’s stock valued at $7,866,000 after purchasing an additional 36,547 shares during the period. Institutional investors own 60.92% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Recommended Story: Hang Seng Index (HSI)

Get a free copy of the Zacks research report on Replimune Group (REPL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.